BioSpace News Archive

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 11:30 a.m. ET.

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual Congress

Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) acceptance of the Investigational New Drug (“IND”) application filed by Eli Lilly and Company

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, hosted a virtual Clinical Day on May 20, 2021 to provide an update on the clinical progress of ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (wet AMD)

Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced today that John Murphy, Ph.D., has joined as Chief Scientific Officer and Greg Hoffman, Ph.D., has joined as Vice President, Discovery & Platform

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced its participation in the following conferences in June.

Konica Minolta Precision Medicine (KMPM), announced today that Tom Schoenherr , Chief Executive Officer of Ambry Genetics, a KMPM company, will present at the third annual AWS Healthcare & Life Science Virtual Symposium on Thursday, May 27, 2021

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, June 3, 2021 at 10:00 am ET.